NASDAQ: ERNA
Ernexa Therapeutics Inc Stock Ownership - Who owns Ernexa Therapeutics?

Insider buying vs selling

Have Ernexa Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Charles Cherington10% Owner2025-06-0921,241,163$0.11
$2.23MBuy
Charles Cherington10% Owner2025-04-023,768,397$0.11
$395.68kBuy

1 of 1

ERNA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ERNA insiders and whales buy or sell their stock.

ERNA Shareholders

What type of owners hold Ernexa Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Charles Cherington543.09%41,659,743$69.99MInsider
Fidelity National Financial Inc500.99%38,430,766$64.56MInsider
Jeffrey Alan Berg272.36%20,892,428$35.10MInsider
Trinad Capital Master Fund Ltd116.02%8,900,093$14.95MInsider
Joseph J. Farricielli Jr.88.06%6,754,611$11.35MInsider
Fidelity National Financial Inc 169.20%5,307,911$8.92MInsider
Matthew Angel45.49%3,489,666$5.86MInsider
John D. Halpern38.15%2,926,551$4.92MInsider
Yiannis Monovoukas21.92%1,681,359$2.82MInsider
Nicholas Jason Singer19.07%1,463,036$2.46MInsider

1 of 3

ERNA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ERNA0.04%99.96%Net Buying
OSRH0.24%99.76%
APLM0.67%0.00%
EDSA18.80%81.20%Net Buying
MRKR2.40%97.60%Net Buying

Ernexa Therapeutics Stock Ownership FAQ

Who owns Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ: ERNA) is owned by 0.65% institutional shareholders, 1,780.39% Ernexa Therapeutics insiders, and 0.00% retail investors. Charles Cherington is the largest individual Ernexa Therapeutics shareholder, owning 41.66M shares representing 543.09% of the company. Charles Cherington's Ernexa Therapeutics shares are currently valued at $68.74M.

If you're new to stock investing, here's how to buy Ernexa Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.